Objective
to assess whether DAPT with ticagrelor plus aspirin reduces the risk of adverse cardiovascular events compared to aspirin alone in patients after CABG for ACS
Study
open-label, registry-based, randomised controlled trial
Population
patients who underwent isolated CABG within 6 weeks of ACS
Endpoints
composite of death, myocardial infarction, stroke or repeat revascularisation at 1 year; major bleeding
Conclusion
In patients who underwent CABG for ACS, ticagrelor plus aspirin did not result in a lower incidence of death, myocardial infarction, stroke, or repeat coronary revascularisation at 1 year when compared with aspirin alone.
Jeppsson et al. NEJM 2025; Sep 1.